Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(29%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
14%
Ph early_phase_1
1
14%
Ph phase_1
1
14%
Ph phase_3
2
29%
Ph phase_4
1
14%

Phase Distribution

2

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(1)
Terminated(1)
Other(3)

Detailed Status

unknown3
Recruiting2
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (16.7%)
Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 32 (33.3%)
Phase 41 (16.7%)

Trials by Status

recruiting229%
unknown343%
completed114%
withdrawn114%

Recent Activity

2 active trials
Showing 5 of 7
recruitingphase_3

Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

NCT07326540
recruiting

Intraventricular Administration of Intracranial Infections Caused by （Carbapenem-resistant Gram-negative Bacilli）CRGNB

NCT06595979
completedphase_1

A Pharmacokinetic Study of Polymyxin B in Healthy Subjects and Subjects With Renal Insufficiency

NCT05359627
withdrawnphase_2

Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria

NCT02134106
unknownearly_phase_1

The Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae

NCT03950544
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07326540Phase 3

Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

Recruiting
NCT06595979

Intraventricular Administration of Intracranial Infections Caused by （Carbapenem-resistant Gram-negative Bacilli）CRGNB

Recruiting
NCT05359627Phase 1

A Pharmacokinetic Study of Polymyxin B in Healthy Subjects and Subjects With Renal Insufficiency

Completed
NCT02134106Phase 2

Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria

Withdrawn
NCT03950544Early Phase 1

The Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae

Unknown
NCT03159078Phase 3

Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens

Unknown
NCT02328183Phase 4

Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7